It has been more than one year since the COVID-19 pandemic hit the world and changed nearly every aspect of our existence. We are adjusting to a new reality in most parts of our lives, as businesses as well as individuals. Although there is still undoubtedly uncertainty in the days ahead, we would like to
VEJLE, Denmark—March 7, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, has obtained approval a Research License from Health Canada under the Cannabis Act. The Research License is a key element in NordicCan’s strategy of obtaining the processing license for cannabinoid oral dosage formats from the
VEJLE, Denmark—March 5, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, today announced that the United States Patent and Trademark Office (USPTO) has issued it two patents: U.S. Patent No. 10,925,853 and US 10,933,017 cover the use of cannabinoids within NordicCan’s oral dosage formats Zapliq Chewable
During the 2021 edition of PLMA online trade show to be held on February 3 and 4, 2021, Fertin Pharma will present its ready-to-license caffeine chewing gum. Together with its subsidiary Tab Labs, Fertin Pharma will present this innovative product, which is a quick and convenient delivery system for that all-important caffeine-induced pick-me-up at the
Full Contract Development and Manufacturing Organization will continue to specialize in innovative cannabinoid solutions for the B2B market MedCan Pharma A/S announced today the launch of a new corporate name and brand identity. The organization will now be known as NordicCan A/S. The new name is reflected in a new logo, domain name, www.nordiccan.com and
Fertin Pharma is very excited about the recent launch of our new Enterprise Resource Planning (ERP) system, which is based on the latest SAP 4/Hana platform. The new system, with more than 1,400 different SAP tiles, supports our long-term growth strategy and strong commitment to customers and partners. It enables us to increase our responsiveness
Peter Halling has been appointed CEO of Fertin Pharma and will join in August 2020. Peter brings extensive experience from working in international environments of production companies in complex and contract-driven markets. He most recently served as an Executive Vice President at Döhler Group but prior to that held various roles at Ingredion and Novozymes.
Succeeds Tom Hoeltgen, who is set to retire in December, 2020 Fertin Pharma, a leading contract development and manufacturing organization (CDMO), has appointed John Stephen as CEO of Tab Labs, its Vancouver-based subsidiary. Stephen has been active in the dietary and supplement field for over 30 years. Fertin, which has four decades of experience and
U.S. Patent No. 10,632,076 B2 further strengthens Fertin Pharma’s intellectual property (IP) portfolio Vejle, Denmark, April 28, 2020 – Fertin Pharma, a contract development and manufacturing organization (CDMO) with more than 40 years of experience, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,632,076 B2. The patent
On 11 March, 2020, the Danish Prime Minister declared a shut-down of parts of the public sector in Denmark due to the development of Covid-19. This means that in-door assemblies with more than 100 attendees are no longer allowed and universities, schools, etc. will be closed for the next two weeks. At Fertin Pharma we
During October 17 and 18th, 2019, Fertin will participate at Supply Side West 2019 in Las Vegas, one of the leading ingredient and solutions tradeshows throughout the health and nutrition industry. Fertin will be presenting its new oral delivery format, Zapliq® a fast liquefiable tablet. This patented technology takes chewable tablets to the next level.
Fertin Pharma works with more than 600 suppliers globally. Søren Laursen is Head of Procurement and responsible for developing and implementing the sustainable sourcing strategy of Fertin Pharma. As part of our ‘Proud to be supporting healthy living’ series, providing insights into the life and work in our company, we asked Søren to tell more
Vejle, Denmark, 2 September 2019 – The shareholders of Fertin Pharma A/S (“Fertin Pharma”) have appointed Marianne Kirkegaard as new Chairman. She will replace Dr. Thomas Werner as of 1 September 2019. The shareholders would like to take the opportunity to thank Dr. Thomas Werner for his valuable contributions as Chairman. New Chairman brings extensive global leadership